Skip to content

Homoeopathic Treatment of Urticaria

A clinical study on the efficacy of Individualized constitutional medicine in cases of Urticaria along with miasmatic study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080069
Enrollment
40
Registered
2025-02-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L509- Urticaria, unspecified

Interventions

Intervention1: Individualized Constitutional Homoeopathic Medicine: Selected medicine will be given on the basis of totality of symptoms and in consultation with posology 30, 200, 1m potency will be p

Sponsors

RBTS Govt Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient confirming with EB00 criteria of ICD 11. Patient in age group of 15-60 years fulfilling the diagnostic criteria. Both male and female. Patients who give their written consent for participation.

Exclusion criteria

Exclusion criteria: Patient below the age of 15 years and above the age of 60 years. Patient suffering from any co-morbidity. Patient who do not give consent for homoeopathic participation. Patient with complaint of Urticaria complicated with other dermatological affection. Pregnant women and lactating mother.

Design outcomes

Primary

MeasureTime frame
At the end of study we expect positive response of chosen homoeopathic medicine upon UrticariaTimepoint: 12 weeks - 15 weeks

Secondary

MeasureTime frame
The study will encourage patients to take homoeopathic medicine in the cases of Urticaria.Timepoint: 12 weeks - 15 weeks

Countries

India

Contacts

Public ContactDr Shashi Bhushan Singh

Department of Organon of Medicine and Homoeopathic Philosophy

dr.neeharikasoni@gmail.com8178340653

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026